Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548582 | 0.92 | MEN1 (0.57) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1548965 | 0.88 | MEN1 (0.61) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4995901 | 0.78 | SPHK2 (0.46) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL19149691 | 0.71 | LMNA (0.56) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1548589 | 0.70 | LMNA (0.50) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL29386910 | 0.70 | MEN1 (0.45) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1548981 | 0.70 | MEN1 (0.45) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1548742 | 0.70 | MEN1 (0.55) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4715435 | 0.69 | LMNA (0.57) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1548782 | 0.69 | MEN1 (0.54) | LMNAMEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-21 | — | — | US | claimed |
| US-10822415-B2 | Methods for enhancing the potency of the immune checkpoint inhibitors | INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE) (FR) | 2020-11-03 | — | — | US | disclosed |
| US-20190031757-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale (FR) | 2019-01-31 | — | — | US | disclosed |
| EP-3407912-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017129769-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, S1PR1 | LMNA 1777/4885MEN1 2111/4885KMT2A 3321/4885 |
| US-20190031757-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | CD274, PDCD1, PDCD1LG2 | LMNA 3972/4885MEN1 304/4885KMT2A 317/4885 |
| US-10822415-B2 | Methods for enhancing the potency of the immune checkpoint inhibitors | CD274, PDCD1, PDCD1LG2 | LMNA 3972/4885MEN1 304/4885KMT2A 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.